MINNETONKA, Minn.--(BUSINESS WIRE)--A.forall’s U.S. subsidiary Milla Pharmaceuticals Inc. announced the launch of the group’s generic version of Precedex®, Dexmedetomidine Hydrochloride Injection 200 ...
Riverside portfolio company A.forall has signed a definitive agreement to sell its retail and hospital business unit to Abacus Medicine. Riverside originally invested in A.forall, formerly known as ...
MINNETONKA, Minn.--(BUSINESS WIRE)--Milla Pharmaceuticals Inc., an A.forall company, announced that its partner, Acella Pharmaceuticals LLC, has just commercialized its Abbreviated New Drug ...
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach ANDERLECHT, Belgium, September 09, 2025--(BUSINESS WIRE)--A.forall is pleased to announce the acquisition of ...
WHITE BEAR LAKE, Minn., January 30, 2025--(BUSINESS WIRE)--A.forall announced through its U.S. subsidiary, Milla Pharmaceuticals Inc., that it has received Abbreviated New Drug Application (ANDA) ...
A.forall, which is backed by The Riverside Company, has acquired Provepharm’s US generics portfolio. No financial terms were disclosed. The deal includes four FDA-approved and marketed sterile ...
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage ...
ANDERLECHT, Belgium--(BUSINESS WIRE)--#FocusToGrow--A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback